Mohamed Abdelhady’s Post

📃Scientific paper: The diagnosis interval influences risk factors of mortality in patients with co-existent active tuberculosis and lung cancer: a retrospective study Abstract: Background Previous studies reported that tuberculosis (TB) is associated with an increased risk of lung cancer or the survival and mortality of lung cancer. However, the impact of coexisting TB on the survival of lung cancer patients was controversial. We aimed to identify risk factors on the survival rate of patients with co-existent active TB and lung cancer. Methods One hundred seventy-three patients diagnosed with active TB and lung cancer from January 2016 to August 2021 in Shanghai pulmonary hospital were selected and divided into two groups (≤ 6 months, > 6 months) according to the diagnosis interval between active TB and lung cancer (the order of diagnosis is not considered). The clinical characteristics and survival were analyzed. Univariate and multivariate logistic regression analyses were used to identify the risk factors for overall survival (OS). Results One hundred seventy-three patients were diagnosed with lung cancer and active TB. The study population exhibited a median age of 64 years, with a majority of 81.5% being male, 58.0% of patients had a history of smoking. Among those involved, 93.6% had pulmonary TB, 91.9% were diagnosed with non-small cell lung cancer (NSCLC), 76.9% were Eastern Cooperative Oncology Group (ECOG) 0–2 and 12.7% were ECOG 3–4. We observed better survival in the > 6 months group compared with the ≤ 6 months group (hazard ratio [HR] 0.456, 95% confidence interval [CI]:0.234–0.889, P  = 0.017). The 1-, 3-, and 5- year OS r... Continued on ES/IODE ➡️ https://etcse.fr/6Wv ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Only a fraction of eligible veterans—3.9%—received lung cancer screening (LCS) before their diagnosis, yet this small group experienced significant benefits. Donna M. Edwards and colleagues published a groundbreaking study in Cancer (2024) that sheds light on the real-world impact of lung cancer screening within the Veterans Health Administration (VA). With lung cancer remaining the leading cause of cancer deaths globally, this study highlights how low-dose CT scans could revolutionize early detection and outcomes. 📊 Key Findings: - Stage Shift: Screened patients were twice as likely to be diagnosed at stage I (52% vs. 27%) and less likely at stage IV (11% vs. 32%). - Survival Rates: Five-year overall survival was markedly higher for screened patients (44.9% vs. 22.3%). Lung cancer-specific survival was also better (59.0% vs. 29.7%). - Mortality Reduction: For screening-eligible veterans, screening decreased lung cancer-specific mortality by 39% (adjusted hazard ratio [aHR] 0.61). Why It Matters: Despite robust evidence supporting LCS, uptake remains limited. Barriers like provider concerns over overdiagnosis and systemic challenges hinder its widespread adoption. Yet, the data underscores that early detection saves lives—highlighting the urgency for broader implementation. 🧠 My Thoughts: As radiologists, we’re accustomed to detecting abnormalities in their earliest stages, and this study reinforces our role in driving innovation. However, we must tackle the persistent challenge of integrating effective screening programs across diverse healthcare systems. The findings call for not only systemic support but also informed dialogue about implementing AI and advanced diagnostics to ensure no patient is left behind. What’s your take? How can we address the barriers to lung cancer screening in real-world practice? Share your thoughts below! Link to the article: https://lnkd.in/d7zDu-fx Read more: https://lnkd.in/d-AYK2re

Improvements in cancer prevention and screening have averted more deaths from five cancer types combined over the past 45 years than treatment advances, according to a modeling study led by researchers at the National Institutes of Health (NIH). The study, published December 5, 2024, in the journal JAMA Oncology, looked at deaths from breast, cervical, colorectal, lung, and prostate cancer that were averted by the combination of prevention, screening, and treatment advances. The researchers focused on these five cancers because they are among the most common causes of cancer deaths and strategies exist for their prevention, early detection, and/or treatment. In recent years, these five cancers have made up nearly half of all new cancer diagnoses and deaths. "Although many people may believe that treatment advances are the major driver of reductions in mortality from these five cancers combined, the surprise here is how much prevention and screening contribute to reductions in mortality," said co-lead investigator Katrina A. B. Goddard, PhD, director of NCI’s Division of Cancer Control and Population Sciences. “Eight out of ten deaths from these five cancers that were averted over the past 45 years were due to advances in prevention and screening.” A single prevention intervention, smoking cessation, contributed the lion’s share of the deaths averted: 3.45 million from lung cancer alone. https://lnkd.in/d4_rsFDs #CancerPrevention #EarlyDetectionSavesLives #CancerScreening #OncologyAwareness #PublicHealthMatters #PreventiveCare #CancerAwareness #HealthEquity #LifeSavingResearch #HealthcareInnovation

A breakthrough cancer immunotherapy is now taking aim at autoimmune disease. It is a miracle: But the young woman had only mild side effects from the cells: a fever and some fatigue, which passed. Three-and-a-half years later, she is off all lupus medication and is a university student studying medical technology. “She’s a person you meet on the street and she’s completely healthy,” Schett says. One fall day in 2020, rheumatologist and immunologist Georg Schett joined three other doctors in a colleague’s spacious office, on the second floor of University Hospital Erlangen, to urge them to try something new. One of them, head of hematology/oncology Andreas Mackensen, was the gatekeeper of a treatment Schett sought to access: a pioneering, genetically engineered cell therapy. Until then, it had only been used in people with cancer. Schett saw potential for much more. The doctors settled themselves at Mackensen’s round conference table. “I have a patient,” Schett began. He told them about Vu-Thi Thu-Thao, a former hip-hop dancer and gymnast; she was 20 years old and had suffered the ravages of lupus, an autoimmune disease, for 4 years. Her joint pain was excruciating, and her lungs, heart, and kidneys were under attack. She had difficulty breathing and pain radiating throughout her chest. What Schett had in mind for his patient: chimeric antigen receptor T-cell (CAR-T) therapy. The treatment involves isolating a patient’s T cells—the sentries of the immune system that strike invaders—and engineering them in a lab to destroy blood cells called B cells that have become cancerous. B cells also help power many autoimmune diseases, and Schett had seen a 2019 study describing mice with lupus restored to good health after CAR-T treatment. He wondered whether the treatment could rescue someone like Thu-Thao. “I said, ‘Why don’t we do this now?’” Schett recalls. The group sat by an expansive window overlooking the translational research building for Erlangen’s CAR-T projects. Mackensen and his colleagues, including hematologist-oncologist Dimitrios Mougiakakos and rheumatologist Gerhard Krönke, weighed the proposition. https://lnkd.in/eYHQP8cV

📃Scientific paper: The impact of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer Abstract: Background The COVID-19 pandemic has affected the entire global healthcare system, including oncological care. This study investigated the effects of the COVID-19 pandemic on the diagnosis, stage, and treatment of esophagogastric cancer in the Netherlands. Methods Patients diagnosed in 2020 were divided into 5 periods, based on the severity of the COVID-19 pandemic in the Netherlands, and compared to patients diagnosed in the same period in the years 2017–2019. Patient characteristics and treatments were evaluated for esophageal cancer (EC) and gastric cancer (GC) separately. Results The number of esophagogastric cancer diagnoses decreased prominently during the first 2 months of the COVID-19 pandemic. During this period, a significantly higher percentage of GC patients was diagnosed with incurable disease (52.5% in 2017–2019 and 67.7% in 2020, p = 0.011). We observed a significant reduction in the percentage of patients with potentially curable EC treated with resection and neoadjuvant chemoradiotherapy (from 35.0% in 2017–2019 to 27.3% in 2020, p < 0.001). Also, patients diagnosed with incurable GC were treated less frequently with a resection (from 4.6% in 2017–2019 to 1.5% in 2020, p = 0.009) in the second half of 2020. Conclusions Compared to previous years, the number of esophagogastric cancer diagnoses decreased in the first 2 months of the COVID-19 pandemic, while an increased percentage of patients was diagnosed with incurable disease. Both in the curative... Continued on ES/IODE ➡️ https://etcse.fr/cBmaP ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Global, regional, and national time trends in cancer mortality attributable to high fasting plasma glucose: an age-period cohort analysis Abstract: Background High fasting plasma glucose (HFPG) is the fastest-growing risk factor for cancer deaths worldwide. We reported the cancer mortality attributable to HFPG at global, regional, and national levels over the past three decades and associations with age, period, and birth cohort. Methods Data for this study were retrieved from the Global Burden of Disease Study 2019, and we used age-period-cohort modelling to estimate age, cohort and period effects, as well as net drift (overall annual percentage change) and local drift (annual percentage change in each age group). Results Over the past 30 years, the global age-standardized mortality rate (ASMR) attributable to HFPG has increased by 27.8%. The ASMR in 2019 was highest in the male population in high sociodemographic index (SDI) areas (8.70; 95% CI, 2.23–18.04). The net drift for mortality was highest in the female population in low SDI areas (2.33; 95% CI, 2.12–2.55). Unfavourable period and cohort effects were found across all SDI quintiles. Cancer subtypes such as "trachea, bronchus, and lung cancers", "colon and rectal cancers", "breast cancer" and "pancreatic cancer" exhibited similar trends. Conclusions The cancer mortality attributable to HFPG has surged during the past three decades. Unfavourable age-period-cohort effects on mortality were observed across all SDI quintiles, and the cancer mortality attributable to HFPG is expected to continue to increase rapidly in the future, particularly in lower SDI l... Continued on ES/IODE ➡️ https://etcse.fr/Tj9v2 ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study Abstract: BACKGROUND: Treatment of cancer patients in certified cancer centers, that meet specific quality standards in term of structures and procedures of medical care, is a national treatment goal in Germany. However, convincing evidence that treatment in certified cancer centers is associated with better outcomes in patients with pancreatic cancer is still missing. METHODS: We used patient-specific information (demographic characteristics, diagnoses, treatments) from German statutory health insurance data covering the period 2009–2017 and hospital characteristics from the German Standardized Quality Reports. We investigated differences in survival between patients treated in hospitals with and without pancreatic cancer center certification by the German Cancer Society (GCS) using the Kaplan–Meier estimator and Cox regression with shared frailty. RESULTS: The final sample included 45,318 patients with pancreatic cancer treated in 1,051 hospitals (96 GCS-certified, 955 not GCS-certified). 5,426 (12.0%) of the patients were treated in GCS-certified pancreatic cancer centers. Patients treated in certified and non-certified hospitals had similar distributions of age, sex, and comorbidities. Median survival was 8.0 months in GCS-certified pancreatic cancer centers and 4.4 months in non-certified hospitals. Cox regression adjusting for multiple patient and hospital characteristics yielded a significantly lower hazard of long-term, all-cause mortality in patients treated in GCS-c... Continued on ES/IODE ➡️ https://etcse.fr/5B1 ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Utilization and short-term outcomes of percutaneous left atrial appendage occlusion in patients with cancer Abstract: Background Percutaneous left atrial appendage occlusion (LAAO) has been rapidly evolving since FDA’s approval in 2015 and has become more of a same-day-discharge procedure. Cancer patient with atrial fibrillation/flutter (AF) population can benefit from the procedure but the in-hospital outcomes and readmission data were rarely studied. Objectives We investigated the utilization, in-hospital and readmission outcomes in cancer patients with AF who underwent LAAO. Methods Data were derived from the National Inpatient Sample and National Readmissions Database from 2016 to 2019. Patients with primary diagnosis of AF admitted for LAAO (ICD-10 code 02L73DK) were grouped by cancer as a secondary diagnosis. We assessed in-hospital mortality, length of stay, total hospital charges, and complications. Thirty-day readmission rates were compared. Results LAAO was performed in 60,380 patients with AF and 3% were cancer patients. There were no differences in in-hospital mortality and total hospital charges; however, cancer patients tended to have longer hospital stay (1.59 ± 0.11 vs. 1.32 ± 0.02, p  = 0.013). Among complications, cancer patients had higher rates in open or percutaneous pericardial drainage (adjusted odds ratio [aOR] 2.38; 95% confidence interval [CI] 1.19–4.76) and major bleeding events (aOR 7.07; 95% CI 1.82–27.38). There was no statistical significance of 30-day readmission rates between patients with and without cancer (10.0% vs. 9.1%, p  = 0.34). The most ... Continued on ES/IODE ➡️ https://etcse.fr/axS ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Esophageal cancer awareness is a crucial topic that deserves attention. It is essential to spread awareness about this disease to improve early detection and treatment outcomes. Esophageal cancer occurs when malignant cells form in the tissues of the esophagus, the muscular tube that connects the throat to the stomach. There are several risk factors associated with esophageal cancer, including tobacco use, heavy alcohol consumption, obesity, and certain medical conditions such as gastroesophageal reflux disease (GERD) and Barrett's esophagus. Individuals need to be aware of these risk factors and take steps to reduce their risk. Symptoms of esophageal cancer can vary and may include difficulty swallowing, chest pain, weight loss, and persistent heartburn. It is essential to consult a healthcare professional for further evaluation if any of these symptoms are present. Early detection of esophageal cancer is critical to improving treatment outcomes. Regular screenings and diagnostic tests can help identify the disease in its early stages when it is more treatable. Treatment options for esophageal cancer may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches. In addition to promoting awareness, it is also essential to support individuals affected by esophageal cancer. This can be done through fundraising events, support groups, and educational resources. By raising awareness about esophageal cancer, we can help ensure that individuals at risk are informed about the disease and have access to the necessary resources for prevention, early detection, and treatment. Together, we can make a difference in the fight against esophageal cancer.

Author Dr Fermin Celma. GcMAF and Multiple Myeloma. A study investigated the effects of GcMAF on human multiple myeloma cells (KMS-12-BM) and human macrophages (CRL9853). The results showed that GcMAF decreased the viability of multiple myeloma cells in a dose-dependent manner. Additionally, GcMAF activated human macrophages, which then phagocytosed (engulfed and digested) the myeloma cancer cells. This dual action—direct inhibition of cancer cell viability and activation of macrophages—suggested that GcMAF could be a promising immunotherapeutic agent.I therefore trialed this in our clinic. We have many case studies from our clinic where GcMAF is one of the therapies that we implement. 1. A case study focused on a 55-year-old male with multiple myeloma. This study highlighted the importance of innovative treatments and potential for new therapies to improve patient outcomes. The patients presented with symptoms like exertional fatigue and were diagnosed with symptomatic multiple myeloma. The study emphasized the need for comprehensive diagnostic work-ups and personalized treatment plans to manage the disease effectively. 2. 2nd case study, we examined the effects of GcMAF on a patient with multiple myeloma. The patient received GcMAF treatment, which led to a significant reduction in tumour size and an improvement in overall health. This study clearly demonstrats that the patient experienced fewer symptoms and better quality of life with GcMAF. This case highlights the potential benefits of GcMAF as part of a comprehensive treatment plan for multiple myeloma. 3. Male 36 years old, very athletic. The big issue he presented with was shortness of breath, also called dyspnea, which is a common symptom of multiple myeloma, he had a persistent cough, which also caused some bleeding. He felt he couldn't breathe, which caused the symptoms to exasperate. Following the first session of nebuliser, he coughed more for 5 minutes, the cough soon subsided, and his breathing became more normalised. With each day that passed, the coughing decreased. His oxygen levels increased. Within one week, he gained a much better quality of life. He remained in close proximity for one month to the clinic. He left with a reduction of 30% and a better outlook. We implemented nebulised gcmaf with sub-c injection at 2500ng daily in this case. Since using Gcmaf for not only multiple myeloma but other types of cancers, our results have improved. Please note that GcMAF is legal to use in all forms of administration in Mexico. Also note that GcMAF only formed part of the protocol. Our double blind studies certainly have a better outcome with all forms of Cancer than those taking the plasibo. I find Gcmaf very useful in the cases of those on the spectrum of Autism, cancer, MS, parkinsonism, HIV, HSV and dementia. We purchased gcmaf from www.dubaibioremedix.com Author Dr Fermin Celma #Drfermincelma #gcmaf #multiplemyelomaawareness #cancerawareness #dubaibioremedix